{
  "ticker": "SNT",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02969343",
  "id": "02969343",
  "pages": 4,
  "price_sensitive": false,
  "date": "20250715",
  "time": "0926",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250715/pdf/06lt27lwx90zlf.pdf",
  "summary": "### Material Information (Clinical Trial Update - Syntara Limited ASX:SNT):  \n\n- **First patient dosed** in **Phase 1c SATELLITE trial** for topical **SNT-6302** (keloid scar treatment).  \n- **Key trial metrics**:  \n  - Open-label, placebo-controlled (for multi-keloid patients).  \n  - Up to **20 participants**, 3-month treatment period.  \n  - Primary focus: **safety, tolerability, scar volume reduction, symptom relief**.  \n- **Upcoming catalyst**: **Phase 1 trial for SNT-9465** (hypertrophic scars) expected **late July 2025**.  \n- **Market context**: Keloid/hypertrophic scar market estimated at **>US$3.5bn annually**.  \n\n*Note: No material financial/capital raising details disclosed.*",
  "usage": {
    "prompt_tokens": 2526,
    "completion_tokens": 183,
    "total_tokens": 2709,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-14T23:53:32.395054"
}